Search
Ketamine Treatment Options
A collection of 517 research studies where Ketamine is the interventional treatment. These studies are located in the United States. Ketamine is used for conditions such as Pain, Major Depressive Disorder and Depression.
505 - 516 of 517
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients
Withdrawn
Often, patients transported by aeromedical systems do not receive enough medication to control and relieve their pain. The purpose of this study is to determine if pain treatment with intravenous (IV) ketamine is a better way to treat aeromedical patients' pain than the current treatment practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2012
Locations: University of Utah Medical Center, Salt Lake City, Utah
Conditions: Trauma, Pain
Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects
Completed
This study examines the interactive effects of ketamine and nicotine.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/08/2012
Locations: Veterans Administration Hospital, West Haven, Connecticut
Conditions: Healthy Subjects
Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED)
Completed
This study is a clinical trial of moderate sedation with propofol versus moderate sedation with ketamine for procedural sedation in the Emergency Department.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2012
Locations: Hennepin County Medical Center, Minneapolis, Minnesota
Conditions: Sedation
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
Terminated
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2012
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Pain, Cancer
Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery
Completed
The purpose of this research study is to evaluate the safety and analgesic efficacy of PMI-150 (intranasal ketamine) compared to placebo in patients with acute post-operative pain following orthopedic trauma, injury, or surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/10/2012
Locations: Jefferson Clinic, Birmingham, Alabama +15 locations
Conditions: Pain, Postoperative
Ketamine Frequency Treatment for Major Depressive Disorder
Withdrawn
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range of options, the response rate, defined as the number of subjects who have a 50% reduction in depressive symptoms, is estimated to be around 65%.
This randomized clinical trial will examine the frequency of treatment with ketamine in patients with treatment-resistant de... Read More
Gender:
ALL
Ages:
Between 30 years and 65 years
Trial Updated:
06/03/2011
Locations: St. Mary's Duluth Clinic Health System, Duluth, Minnesota
Conditions: Treatment Resistant Depression
Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair
Completed
The purpose of this study is to compare how well three different doses of ketamine, given as a spray into the nose, help to sedate children and help them tolerate repairs of cuts on their faces.
Gender:
ALL
Ages:
Between 1 year and 7 years
Trial Updated:
07/21/2010
Locations: Hasbro Children's Hospital, Providence, Rhode Island
Conditions: Laceration
Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS
Completed
Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition. There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate (NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be effective in the treatment of CRPS, resulting in complete remission of the disease in some patients. The purpose of this study is to evaluate intravenous outpatient infusion of sub-anesthetic doses of ketamine for the treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/15/2010
Locations: Drexel University College of Medicine Department of Neurology, Philadelphia, Pennsylvania
Conditions: Complex Regional Pain Syndrome
Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease
Terminated
The purpose of this pilot study is to provide a preliminary assessment of the feasibility and efficacy of intravenous ketamine in controlling pain in patients with sickle cell disease (who are admitted to the hospital with severe, acute pain crisis, and who have been resistant to intravenous narcotics).
Gender:
ALL
Ages:
Between 7 years and 18 years
Trial Updated:
03/12/2009
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Sickle Cell Disease
Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)
Completed
To assess the effects of nasal corticosteroid treatment on the rate and extent of intranasal absorption of PMI-150 (intranasal ketamine HCl)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/21/2008
Locations: Not set, Baltimore, Maryland
Conditions: Healthy
Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine
Unknown
This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2008
Locations: Javelin Pharmaceuticals, Cambridge, Massachusetts
Conditions: Pharmacokinetics
Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine
Completed
This is an open label, single-center study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2008
Locations: Javelin Pharmaceuticals, Cambridge, Massachusetts
Conditions: Healthy
505 - 516 of 517